Abstract
Objective: To evaluate the efficacy of the ranibizumab intravitreal injection in idiopathic choroidal neovascularization. Material and methods: The study included 3 patients (4 eyes), aged 17, 37 and 46, with visual acuity deterioration, warping and distortion of the central image lasting for 2–5 weeks. Inflammatory background of the disease was excluded. The baseline examination and follow-up included the best corrected visual acuity (BCVA), fluorescein angiography and central retinal thickness (CRT) analysis using optical coherence tomography (OCT). When ICNV was diagnosed, intravitreal injections of ranibizumab were administered. Results: During the first follow-up test, 3 eyes showed improvement of BCVA, and in the fourth eye BCVA remained unchanged. In funduscopy, all patients showed reduced haemorrhage and oedema of the central retina. The OCT showed a reduction of the CRT and improvement in the morphology of the macula. The observation period ranged from 4 to 55 months, and the number of repeated injections during the observation ranged from 2 to 5. Conclusions: Injections of ranibizumab into the vitreous brought a significant improvement in the function of the treated eye, and in the morphology of the retina in OCT.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
